Artificial Intelligence (AI) and Organoids: Revolutionizing Cancer Drug Discovery

The Convergence of Two Cutting-Edge Technologies

The fight against cancer has entered a transformative era with the integration of artificial intelligence (AI) and patient-derived organoid technology, reshaping how novel therapies are discovered and developed. Traditional drug discovery is often slow, costly, and hampered by inadequate preclinical models that fail to predict clinical outcomes. In contrast, the synergy between AI’s computational power and the biological precision of 3D organoids is accelerating precision medicine. This approach enables faster identification of drug candidates, more accurate prediction of patient responses, and a shorter path from lab to clinic. At the AACR 2025 meeting, Signet Therapeutics showcased this innovation by unveiling SIGX1094R, the first AI-designed, organoid-validated targeted therapy for diffuse gastric cancer (DGC). This milestone highlights the potential of combining computational biology and advanced tissue models to overcome the limitations of conventional drug development.

The Role of AI in Accelerating Drug Discovery

AI-Powered Target Identification and Drug Design

AI algorithms, trained on genomics, proteomics, and clinical datasets, are now capable of identifying novel drug targets with remarkable precision. For instance, machine learning models (AI models) identified used real-world genomic data to identify Focal Adhesion Kinase (FAK)  overexpression in DGC and its role in metastasis. In collaboration with XtalPi, quantum physics-based simulations were employed to optimize SIGX1094R’s molecular structure, enabling dual inhibition of FAK and SRC, a resistance mechanism missed by prior FAK inhibitors.

Predictive Modeling for Efficacy and Toxicity

AI also streamlines drug development by predicting binding affinities, pharmacokinetics, and toxicity, thus improving potency and reducing trial-and-error cycles. It also identifies promising combination therapies, such as pairing with KRAS or EGFR inhibitors. By integrating AI early in the pipeline, the drug discovery timeline was reduced from several years to just three, enabling rapid achievement of Investigational New Drug (IND) approval.

Organoids: Mimicking Human Tumors in the Lab

Why Organoids Are Game-Changers

Organoids are three-dimensional (3D), miniaturized, organ-like structures grown in the laboratory from a person’s stem cells or tumor cells. These structures are self-organized tissue cultures that replicate key features of human tissues and organs, including their cellular composition, spatial organization, and some functional properties. Unlike traditional 2D cell cultures or animal models, organoids are composed of multiple cell types and can mimic the histologic, genomic, and molecular characteristics of the original tissue from which they were derived.

When generated from tumor cells, these cancer organoids (also known as tumoroids) closely resemble the original tumor in terms of architecture and biological behavior, making them powerful models for studying cancer development and progression. Similarly, organoids derived from healthy stem cells can model normal tissue development and function.

Signet’s organoid-based platform validated AI-predicted drug candidates in biologically relevant environments, tested efficacy across diverse patient subtypes, and minimized reliance on animal models that often fail to predict clinical outcomes.

Organoid-Driven Validation of SIGX1094R

Preclinical studies using DGC organoid models showed SIGX1094R outperforming existing FAK inhibitors. Additional validation through patient-derived xenografts (PDXs) confirmed tumor suppression, while ascites models demonstrated significant reduction in malignant fluid buildup. These preclinical successes were later echoed in Phase I trials, validating organoids’ predictive capabilities.

Regulatory Success

The SIGX1094R therapy received FDA Fast Track and Orphan Drug Designation between 2024 and 2025, and gained IND approvals from both the U.S. FDA and China’s NMPA .

The Future: AI + Organoids as the New Gold Standard?

The success of SIGX1094R showcases how AI and organoids are setting a new benchmark in oncology drug development, lowering failure rates through precise target selection, shrinking development timelines from a decade to just a few years, and enabling personalized medicine through patient-specific organoid testing. Future advancements will include AI-designed combination therapies for resistant cancers, organoid biobanks to forecast drug responses at the population level, and automated high-throughput screening powered by robotics and AI.

Conclusion

The convergence of AI and organoid technologies is revolutionizing cancer drug discovery, shifting the paradigm from a slow and uncertain process to one that is rapid, precise, and centered on patient biology. The development of SIGX1094R, from AI-based design to clinical validation, signals a new era in oncology where every phase of drug development benefits from machine learning and human-relevant models. As these tools become more widely adopted, they hold the promise of delivering highly tailored and effective treatments even for the most challenging cancers.

Reference

Abstract 3018: Discovery of SIGX1094R, a novel FAK inhibitor simultaneously blocking FAK and SRC signaling

 

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1.  Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217
2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. bioRxiv 2025.04.15.648836v1 https://www.biorxiv.org/content/10.1101/2025.04.15.648836v1
3.  American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity  Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

 

 

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

 

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)